Any current/future capex/capital investment/strategic investment?

Emami has made investments behind rural expansion ("Project Khoj"), adding around 11,000 towns last year and targeting around 8,000 more towns by end of next financial year, aiming to reach about 60,000 towns and villages. There are ongoing investments in strengthening manpower, modern trade, and e-commerce capabilities, particularly focusing on digital-first brands and D2C (direct-to-consumer) initiatives. Emami continues to invest in advertising (around 17% of sales expected), including male grooming and healthcare categories, indicating capital allocation to marketing and brand-building

Future growth expectations in sales/revenue/volumes?

Domestic business growth expected at 8%-10% if rural demand sustains (Page 9, 13). International business anticipated to grow about 20% this year (Page 13, 15). Healthcare segment targeted for 15%-20% growth (Page 13). Start-up/D2C businesses like The Man Company projected to grow 50%-60% in FY '24, accelerating from 40% growth in FY '23 (Pages 7, 8). Kesh King portfolio expected to achieve around 10% growth in the current quarter (Page 9). New product development focused mainly on digital-first/D2C brands for premium categories (Page 12). Rural market growth is a key focus; infrastructure inv

Future growth expectations in earnings/operating earnings/profits/EPS?

Domestic business expected to grow at 8-10% in FY '24, driven by rural recovery and portfolio strength excluding summer portfolio challenges. International business projected to grow around 20% in FY '24, with stabilization in key markets. Healthcare segment anticipates 15-20% growth. The Man Company expected to achieve profitability in next fiscal year. Gross margins expected to expand by about 150 basis points due to easing raw material costs. Advertising & Promotion (A&P) spend to remain around 17%, supporting brand growth. EBITDA margins excluding strategic investments close to pre-COVID l

Emami LtdQ4 FY23Personal Products

Emami Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹375.05P/E: 21.6Market Cap: ₹16.4K CrSector: Personal Products

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

Domestic business growth expected at 8%-10% if rural demand sustains (Page 9, 13).
International business anticipated to grow about 20% this year (Page 13, 15).
Healthcare segment targeted for 15%-20% growth (Page 13).
Start-up/D2C businesses like The Man Company projected to grow 50%-60% in FY '24, accelerating from 40% growth in FY '23 (Pages 7, 8).
Kesh King portfolio expected to achieve around 10% growth in the current quarter (Page 9).
New product development focused mainly on digital-first/D2C brands for premium categories (Page 12).
Rural market growth is a key focus; infrastructure investments made for long-term growth (Page 16).
Despite weak summer portfolio, other categories like male grooming, pain management, and healthcare are firing and showing positive momentum (Pages 7, 9, 10).
Organic volume growth was negative last quarter but expected to improve with new initiatives (Page 12).

Margin guidance

Category 3

Domestic business expected to grow at 8-10% in FY '24, driven by rural recovery and portfolio strength excluding summer portfolio challenges.
International business projected to grow around 20% in FY '24, with stabilization in key markets.
Healthcare segment anticipates 15-20% growth.
The Man Company expected to achieve profitability in next fiscal year.
Gross margins expected to expand by about 150 basis points due to easing raw material costs.
Advertising & Promotion (A&P) spend to remain around 17%, supporting brand growth.
EBITDA margins excluding strategic investments close to pre-COVID levels (26.7%), with overall margin expansion anticipated.
Long-term investments in distribution, digital-first brands, and modern trade/e-commerce expected to fuel sustained growth.
Emphasis on volume-driven growth for FY '24, with limited reliance on pricing increases due to material cost trends.

See what Emami Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

- The transcript does not explicitly mention any current or future fundraising plans through debt or equity. - There is discussion about divesting non-core assets and reducing pledged shares, specifically a hospital deal that, if it doesn't materialize, will lead to alternative plans being explored. - No direct mention of raising new debt or equity capital was made during the call. - The focus appears to be on internal investments in distribution expansion, digital-first brands, and business growth without reference to new external fundraising. In summary, no clear indication of planned new fundraising through debt or equity was disclosed in the provided transcript.

Order book

The transcript does not explicitly mention current or expected order book or pending orders for Emami Limited. However, relevant insights related to business outlook and growth prospects are: - The deal mentioned (likely an acquisition) is signed and awaiting government approval, expected to conclude within 3 to 4 weeks (Page 14). - Business growth and demand expected to improve, especially from rural markets once demand picks up (Page 16). - Investments behind rural expansion and digital-first brands signal building future growth pipeline (Pages 11, 16). - Overall, management emphasizes long-term investment and growth, expecting 8-10% domestic growth, 15-20% growth in healthcare, and 20% in international business (Pages 9, 13). - Strategic inventory is maintained for raw materials and packaging, especially in Bangladesh, indicating smooth operational continuity (Page 15). No direct numeric figures on order book or pending orders are provided in the transcript.

See what Emami Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Emami has made investments behind rural expansion ("Project Khoj"), adding around 11,000 towns last year and targeting around 8,000 more towns by end of next financial year, aiming to reach about 60,000 towns and villages.
There are ongoing investments in strengthening manpower, modern trade, and e-commerce capabilities, particularly focusing on digital-first brands and D2C (direct-to-consumer) initiatives.
Emami continues to invest in advertising (around 17% of sales expected), including male grooming and healthcare categories, indicating capital allocation to marketing and brand-building.
The company is investing in new-age start-ups like The Man Company and Brillare Science, with expectations of 50-60% growth in these start-ups in the current year.
Strategic investment impairments have been recognized (e.g., Brillare Science), reflecting ongoing portfolio assessments but also a focus on scaling these investments.
Discussions on divesting non-core assets and reducing promoter share pledges are ongoing, implying a focus on asset monetization to optimize capital structure.

Track Emami Ltd — get its next earnings analysis in your feed

How does Emami Ltd rank vs peers in Personal Products?

Pro feature

ThisEmami Ltd

Rev 4Mar 3

See where Emami Ltd sits in Personal ProductsSee which companies these are, and every other name in the sector.Open rankings

How does Emami Ltd rank in Personal Products?

Compare Emami Ltd against every Personal Products company (Q4 FY23) on revenue, margins and earnings-call signals.

View Personal Products leaderboard →

What Emami Ltd's management said in earlier quarters

Others in Personal Products this season

Anondita Medicare Ltd (Q3 FY26)
Revenue from operations (Standalone) for H1 FY26: ₹4,765.06 lakh; H1 FY25: ₹2,497.06 lakh; YoY growth: 91% (Page 26) . Key investor presentation takeaways from
Bajaj Consumer (Q2 FY27)
Q2 FY27 Net Sales Value: INR 332.7 Cr., up 27.3% YoY (Page 23) . Key investor presentation takeaways from Bajaj Consumer Care Ltd's Q2 FY27 investor presentatio
Anondita Medicare Ltd (Q4 FY26)
Current unexecuted order book stands at approximately INR137 crores, which remains intact from the previous year. Key concall takeaways from Anondita Medicare…
Cupid Ltd (Q4 FY24)
6,289 Lakhs, up 57.04% QoQ and 51.59% YoY from Rs. Key concall takeaways from Cupid Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.

Compare:vs Godrej Consumer Products Ltd vs Dabur India Ltd vs Colgate-Palmolive (India) Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →